Research Progress of Targeted Therapy in Atherosclerosis Based on the ApoA- I
DOI:
https://doi.org/10.61173/ave6de09Keywords:
Targeted therapy, atherosclerosis, ApoA-I, chronic inflammatory diseaseAbstract
The chronic inflammatory disease atherosclerosis, is caused by the buildup of plaque within the arteries. This may result in the narrowing and stiffening of the lumen. Current studies have shifted towards innovative treatments that target specific proteins central to atherosclerosis development. The subject of focus in this article is ApoA-I, a crucial component in the mechanism of reverse cholesterol transportation. ApoA-I’s high effectiveness in interacting with ABCA1 and ABCG1 receptors on membranes facilitates the extraction of phospholipids and cholesterol from foam cells. In vivo experiments suggest that ApoA-I could serve as a novel therapeutic target for coronary atherosclerosis, but its extended effects require further investigation. The last step in the advancements of ApoA-I research would be clinical and human-based trials. As of currently, no human treatment experiments have been carried out, and the effect loss caused by a rejection reaction cannot be ruled out, and more research must be done before it is medically used.References
[1] Cleveland Clinic. Atherosclerosis: Types, Causes, & Treatments. Cleveland Clinic, 2021. [2024-09-07]. https:// my.clevelandclinic.org/health/diseases/16753-atherosclerosisarterial-disease.
[2] John Hopkins Medicine. Atherosclerosis. John Hopkins Medicine, 2023. [2024-09-07]. https://www.hopkinsmedicine. org/health/conditions-and-diseases/atherosclerosis.
[3] Kobiyama K, Ley K. Atherosclerosis. Circ Res, 2018, 123(10): 1118-1120.
[4] ANAI M, SARUWATARI K, IKEDA T, et al. Clinical impact of cerebral infarction in patients with non-small cell lung cancer. Int J Clin Oncol, 2022, 27(5): 863-870.
[5] Xu Fei, Wang Guanghai, Qiu Wei. Changes and Significance of Serum Alpha-Fetoprotein, Albumin, and Apolipoprotein Levels Before and After Liver Cancer Surgery. Chinese Journal of Clinical Oncology and Rehabilitation, 2021, 28(9): 1107- 1110.
[6] Gordon S M, Hofmann S, Askew D S, Davidson W S. High density lipoprotein: It’s not just about lipid transport anymore. Trends Endocrinol Metab, 2011, 22(1): 9-15.
[7] Barker W C, Dayhoff M O. Evolution of lipoproteins deduced from protein sequence data. Comp Biochem Physiol B Comp Biochem, 1977, 57(3): 309-315.
[8] Kardassis D, Mosialou I, Kanaki M, et al. Metabolism of HDL and its regulation. Curr Med Chem, 2014, 21(25): 2864- 2880.
[9] Li W H, Tanimura M, Luo C C, et al. The apolipoprotein multigene family: Biosynthesis, structure, structure-function relationships, and evolution. J Lipid Res, 1988, 29(3): 245-271.
[10] Cabana V G, Siegel J N, Sabesin S M. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res, 1989, 30(1): 39- 49.
[11] Hamilton K K, Zhao J, Sims P J. Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. J Biol Chem, 1993, 268(5): 3632-3638.
[12] Vyletelová V, Nováková M, Pašková Ľ. Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies. Pharmaceuticals (Basel), 2022, 15(10): 1278.
[13] van Linthout S, Spillmann F, Graiani G, et al. Down- Regulation of Endothelial TLR4 Signalling after Apo A-I Gene Transfer Contributes to Improved Survival in an Experimental Model of Lipopolysaccharide-Induced Inflammation. J Mol Med, 2011, 89(2): 151-160.
[14] Ludovico I D, Gisonno R A, Gonzalez M C, et al. Understanding the role of apolipoprotein A-I in atherosclerosis. Post-translational modifications synergize dysfunction?. Biochim Biophys Acta-Gen Subj, 2021, 1865(2): 129732.
[15] Yoshinaga T, Katoh N, Yazaki M, et al. Giant Hepatomegaly with Spleno-testicular Enlargement in a Patient with Apolipoprotein A-I Amyloidosis: An Uncommon Type of Amyloidosis in Japan. Amyloid, 2020, 27(4): 296-299.
[16] Wilson C J, Das M, Jayaraman S, et al. Effects of Disease-Causing Mutations on the Conformation of Human Apolipoprotein A-I in Model Lipoproteins. Biochemistry, 2018, 57(30): 4583-4596.
[17] Tiniakou I, Kanaki Z, Georgopoulos S, et al. Natural human apoA-I mutations L141RPisa and L159RFIN alter HDL structure and functionality and promote atherosclerosis development in mice. Atherosclerosis, 2015, 243(1): 77-85.
[18] Das M, Wilson C J, Mei X, et al. Structural stability and local dynamics in disease-causing mutants of human apolipoprotein A-I: What makes the protein amyloidogenic?. J Mol Biol, 2016, 428(2): 449-462.
[19] Sorci-Thomas M G, Zabalawi M, Bharadwaj M S, et al. Dysfunctional HDL containing L159R ApoA-I leads to exacerbation of atherosclerosis in hyperlipidemic mice. Biochim Biophys Acta, 2012, 1821(3): 502-512.
[20] Gursky O. Crystal structure of Delta(185–243)ApoA-I suggests a mechanistic framework for the protein adaptation to the changing lipid load in good cholesterol. J Mol Biol, 2013, 425(1): 1-16.
[21] Mei X, Atkinson D. Lipid-free Apolipoprotein A-I Structure: Insights into HDL Formation and Atherosclerosis Development. Arch Med Res, 2015, 46(5): 351-360.
[22] Pollard R D, Blesso C N, Zabalawi M, et al. Procollagen C-endopeptidase Enhancer Protein 2 (PCPE2) Reduces Atherosclerosis in Mice by Enhancing Scavenger Receptor Class B1 (SR-BI)-mediated High-density Lipoprotein (HDL)- Cholesteryl Ester Uptake. J Biol Chem, 2015, 290(25): 15496- 15511.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
